Loading…
Clinical associations of serum interleukin-17 in systemic lupus erythematosus
Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. We characterized clinical associations of serum IL-17 in SLE. We quantified IL-17 in serum samples from 98 SLE pa...
Saved in:
| Published in: | Arthritis research & therapy 2013-08, Vol.15 (4), p.R97-R97, Article R97 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93 |
| container_end_page | R97 |
| container_issue | 4 |
| container_start_page | R97 |
| container_title | Arthritis research & therapy |
| container_volume | 15 |
| creator | Vincent, Fabien B Northcott, Melissa Hoi, Alberta Mackay, Fabienne Morand, Eric F |
| description | Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. We characterized clinical associations of serum IL-17 in SLE.
We quantified IL-17 in serum samples from 98 SLE patients studied cross-sectionally, and in 246 samples from 75 of these patients followed longitudinally over two years. Disease activity was recorded using the SLE Disease Activity Index (SLEDAI)-2k. Serum IL-6, migration inhibitory factor (MIF), and B cell activating factor of the tumour necrosis factor family (BAFF) were also measured in these samples.
Serum IL-17 levels were significantly higher in SLE patients compared to healthy donors (P |
| doi_str_mv | 10.1186/ar4277 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3979031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534783415</galeid><sourcerecordid>A534783415</sourcerecordid><originalsourceid>FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93</originalsourceid><addsrcrecordid>eNp1kktr3DAUhUVpadKk_QnBUCjdOLHe1iYQhj4CKdm0ayHLV4kaWZpIdmD-fTw4mXYgQQs97neOLkdC6BNuTjFuxZnJjEj5Bh1iJttaUEHe7tacHaAPpfxtGkIUYe_RAaFKtEyJQ_RrFXz01oTKlJKsN6NPsVTJVQXyNFQ-jpADTHc-1ljO26psygiDt1WY1lOpIG_GWxjMmMpUjtE7Z0KBj0_zEfrz_dvv1c_66vrH5eriqu5YS8e6hY5jIbDqiBJGNs4aQgnvcascSMUBhIVeWdNjJygmnXJSgaTWsJ63naJH6HzxXU_dAL2FOGYT9Dr7weSNTsbr_Ur0t_omPWiqpGoong3UYtD59IrBfsWmQS8Zz9qvT5fndD9BGfXgi4UQTIQ0FY05k5xRyrbo5wW9MQG0jy7NZnaL6ws-Ay1lmM_U6QvUPPptzimC8_P5nuDLIrA5lZLB7RrHjd5-h3-tnvyf0w57fn_6CARvsj0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547543347</pqid></control><display><type>article</type><title>Clinical associations of serum interleukin-17 in systemic lupus erythematosus</title><source>PubMed Central</source><creator>Vincent, Fabien B ; Northcott, Melissa ; Hoi, Alberta ; Mackay, Fabienne ; Morand, Eric F</creator><creatorcontrib>Vincent, Fabien B ; Northcott, Melissa ; Hoi, Alberta ; Mackay, Fabienne ; Morand, Eric F</creatorcontrib><description>Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. We characterized clinical associations of serum IL-17 in SLE.
We quantified IL-17 in serum samples from 98 SLE patients studied cross-sectionally, and in 246 samples from 75 of these patients followed longitudinally over two years. Disease activity was recorded using the SLE Disease Activity Index (SLEDAI)-2k. Serum IL-6, migration inhibitory factor (MIF), and B cell activating factor of the tumour necrosis factor family (BAFF) were also measured in these samples.
Serum IL-17 levels were significantly higher in SLE patients compared to healthy donors (P <0.0001). No correlation was observed between serum IL-17 and SLEDAI-2k, at baseline or during longitudinal follow-up. However, we observed that SLEDAI-2k was positively correlated with IL-17/IL-6 ratio. Serum IL-17 was significantly increased in SLE patients with central nervous system (CNS) disease (P = 0.0298). A strong correlation was observed between serum IL-17 and IL-6 (r = 0.62, P <0.0001), and this relationship was observed regardless of disease activity and persisted when integrating cytokine levels over the period observed (r = 0.66, P <0.0001). A strong correlation of serum IL-17 was also observed with serum BAFF (r = 0.64, P <0.0001), and MIF (r = 0.36, P = 0.0016).
Serum IL-17 concentration correlates poorly with SLE disease activity but is significantly elevated in patients with CNS disease. IL-17/IL-6 ratio may be more useful than IL-17 or IL-6 alone to characterize Th17-driven disease, such as SLE. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE.</description><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>EISSN: 1478-6354</identifier><identifier>DOI: 10.1186/ar4277</identifier><identifier>PMID: 23968496</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Autoimmunity ; Computer software industry ; Cross-Sectional Studies ; Cytokines - blood ; Development and progression ; Enzyme-Linked Immunosorbent Assay ; Female ; Genetic aspects ; Humans ; Interleukin-17 - blood ; Interleukin-17 - immunology ; Interleukin-6 - blood ; Interleukin-6 - immunology ; Interleukins ; Lupus Erythematosus, Systemic - blood ; Lupus Erythematosus, Systemic - immunology ; Male ; Medical research ; Medicine, Experimental ; Middle Aged ; Physiological aspects ; Severity of Illness Index ; Systemic lupus erythematosus</subject><ispartof>Arthritis research & therapy, 2013-08, Vol.15 (4), p.R97-R97, Article R97</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>Copyright © 2013 Vincent et al.; licensee BioMed Central Ltd. 2013 Vincent et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93</citedby><cites>FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979031/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979031/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23968496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vincent, Fabien B</creatorcontrib><creatorcontrib>Northcott, Melissa</creatorcontrib><creatorcontrib>Hoi, Alberta</creatorcontrib><creatorcontrib>Mackay, Fabienne</creatorcontrib><creatorcontrib>Morand, Eric F</creatorcontrib><title>Clinical associations of serum interleukin-17 in systemic lupus erythematosus</title><title>Arthritis research & therapy</title><addtitle>Arthritis Res Ther</addtitle><description>Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. We characterized clinical associations of serum IL-17 in SLE.
We quantified IL-17 in serum samples from 98 SLE patients studied cross-sectionally, and in 246 samples from 75 of these patients followed longitudinally over two years. Disease activity was recorded using the SLE Disease Activity Index (SLEDAI)-2k. Serum IL-6, migration inhibitory factor (MIF), and B cell activating factor of the tumour necrosis factor family (BAFF) were also measured in these samples.
Serum IL-17 levels were significantly higher in SLE patients compared to healthy donors (P <0.0001). No correlation was observed between serum IL-17 and SLEDAI-2k, at baseline or during longitudinal follow-up. However, we observed that SLEDAI-2k was positively correlated with IL-17/IL-6 ratio. Serum IL-17 was significantly increased in SLE patients with central nervous system (CNS) disease (P = 0.0298). A strong correlation was observed between serum IL-17 and IL-6 (r = 0.62, P <0.0001), and this relationship was observed regardless of disease activity and persisted when integrating cytokine levels over the period observed (r = 0.66, P <0.0001). A strong correlation of serum IL-17 was also observed with serum BAFF (r = 0.64, P <0.0001), and MIF (r = 0.36, P = 0.0016).
Serum IL-17 concentration correlates poorly with SLE disease activity but is significantly elevated in patients with CNS disease. IL-17/IL-6 ratio may be more useful than IL-17 or IL-6 alone to characterize Th17-driven disease, such as SLE. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE.</description><subject>Adult</subject><subject>Autoimmunity</subject><subject>Computer software industry</subject><subject>Cross-Sectional Studies</subject><subject>Cytokines - blood</subject><subject>Development and progression</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Interleukin-17 - blood</subject><subject>Interleukin-17 - immunology</subject><subject>Interleukin-6 - blood</subject><subject>Interleukin-6 - immunology</subject><subject>Interleukins</subject><subject>Lupus Erythematosus, Systemic - blood</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Physiological aspects</subject><subject>Severity of Illness Index</subject><subject>Systemic lupus erythematosus</subject><issn>1478-6354</issn><issn>1478-6362</issn><issn>1478-6354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kktr3DAUhUVpadKk_QnBUCjdOLHe1iYQhj4CKdm0ayHLV4kaWZpIdmD-fTw4mXYgQQs97neOLkdC6BNuTjFuxZnJjEj5Bh1iJttaUEHe7tacHaAPpfxtGkIUYe_RAaFKtEyJQ_RrFXz01oTKlJKsN6NPsVTJVQXyNFQ-jpADTHc-1ljO26psygiDt1WY1lOpIG_GWxjMmMpUjtE7Z0KBj0_zEfrz_dvv1c_66vrH5eriqu5YS8e6hY5jIbDqiBJGNs4aQgnvcascSMUBhIVeWdNjJygmnXJSgaTWsJ63naJH6HzxXU_dAL2FOGYT9Dr7weSNTsbr_Ur0t_omPWiqpGoong3UYtD59IrBfsWmQS8Zz9qvT5fndD9BGfXgi4UQTIQ0FY05k5xRyrbo5wW9MQG0jy7NZnaL6ws-Ay1lmM_U6QvUPPptzimC8_P5nuDLIrA5lZLB7RrHjd5-h3-tnvyf0w57fn_6CARvsj0</recordid><startdate>20130823</startdate><enddate>20130823</enddate><creator>Vincent, Fabien B</creator><creator>Northcott, Melissa</creator><creator>Hoi, Alberta</creator><creator>Mackay, Fabienne</creator><creator>Morand, Eric F</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130823</creationdate><title>Clinical associations of serum interleukin-17 in systemic lupus erythematosus</title><author>Vincent, Fabien B ; Northcott, Melissa ; Hoi, Alberta ; Mackay, Fabienne ; Morand, Eric F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Autoimmunity</topic><topic>Computer software industry</topic><topic>Cross-Sectional Studies</topic><topic>Cytokines - blood</topic><topic>Development and progression</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Interleukin-17 - blood</topic><topic>Interleukin-17 - immunology</topic><topic>Interleukin-6 - blood</topic><topic>Interleukin-6 - immunology</topic><topic>Interleukins</topic><topic>Lupus Erythematosus, Systemic - blood</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Physiological aspects</topic><topic>Severity of Illness Index</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vincent, Fabien B</creatorcontrib><creatorcontrib>Northcott, Melissa</creatorcontrib><creatorcontrib>Hoi, Alberta</creatorcontrib><creatorcontrib>Mackay, Fabienne</creatorcontrib><creatorcontrib>Morand, Eric F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vincent, Fabien B</au><au>Northcott, Melissa</au><au>Hoi, Alberta</au><au>Mackay, Fabienne</au><au>Morand, Eric F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical associations of serum interleukin-17 in systemic lupus erythematosus</atitle><jtitle>Arthritis research & therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2013-08-23</date><risdate>2013</risdate><volume>15</volume><issue>4</issue><spage>R97</spage><epage>R97</epage><pages>R97-R97</pages><artnum>R97</artnum><issn>1478-6354</issn><eissn>1478-6362</eissn><eissn>1478-6354</eissn><abstract>Serum interleukin (IL)-17 concentrations have been reported to be increased in systemic lupus erythematosus (SLE), but associations with clinical characteristics are not well understood. We characterized clinical associations of serum IL-17 in SLE.
We quantified IL-17 in serum samples from 98 SLE patients studied cross-sectionally, and in 246 samples from 75 of these patients followed longitudinally over two years. Disease activity was recorded using the SLE Disease Activity Index (SLEDAI)-2k. Serum IL-6, migration inhibitory factor (MIF), and B cell activating factor of the tumour necrosis factor family (BAFF) were also measured in these samples.
Serum IL-17 levels were significantly higher in SLE patients compared to healthy donors (P <0.0001). No correlation was observed between serum IL-17 and SLEDAI-2k, at baseline or during longitudinal follow-up. However, we observed that SLEDAI-2k was positively correlated with IL-17/IL-6 ratio. Serum IL-17 was significantly increased in SLE patients with central nervous system (CNS) disease (P = 0.0298). A strong correlation was observed between serum IL-17 and IL-6 (r = 0.62, P <0.0001), and this relationship was observed regardless of disease activity and persisted when integrating cytokine levels over the period observed (r = 0.66, P <0.0001). A strong correlation of serum IL-17 was also observed with serum BAFF (r = 0.64, P <0.0001), and MIF (r = 0.36, P = 0.0016).
Serum IL-17 concentration correlates poorly with SLE disease activity but is significantly elevated in patients with CNS disease. IL-17/IL-6 ratio may be more useful than IL-17 or IL-6 alone to characterize Th17-driven disease, such as SLE. The association of other cytokines with serum IL-17 suggests that IL-17 may drive activation of diverse immune pathways in SLE.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23968496</pmid><doi>10.1186/ar4277</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-6354 |
| ispartof | Arthritis research & therapy, 2013-08, Vol.15 (4), p.R97-R97, Article R97 |
| issn | 1478-6354 1478-6362 1478-6354 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3979031 |
| source | PubMed Central |
| subjects | Adult Autoimmunity Computer software industry Cross-Sectional Studies Cytokines - blood Development and progression Enzyme-Linked Immunosorbent Assay Female Genetic aspects Humans Interleukin-17 - blood Interleukin-17 - immunology Interleukin-6 - blood Interleukin-6 - immunology Interleukins Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - immunology Male Medical research Medicine, Experimental Middle Aged Physiological aspects Severity of Illness Index Systemic lupus erythematosus |
| title | Clinical associations of serum interleukin-17 in systemic lupus erythematosus |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T10%3A51%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20associations%20of%20serum%20interleukin-17%20in%20systemic%20lupus%20erythematosus&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Vincent,%20Fabien%20B&rft.date=2013-08-23&rft.volume=15&rft.issue=4&rft.spage=R97&rft.epage=R97&rft.pages=R97-R97&rft.artnum=R97&rft.issn=1478-6354&rft.eissn=1478-6362&rft_id=info:doi/10.1186/ar4277&rft_dat=%3Cgale_pubme%3EA534783415%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b483t-8eb516619b296a70fca2325d189fe795ee6ced9cad1f6312b9f79e73ca4d58b93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1547543347&rft_id=info:pmid/23968496&rft_galeid=A534783415&rfr_iscdi=true |